HIM
LIMNW

HGC Investment Management’s Liminatus Pharma Warrants LIMNW Stock Holding History

HGC Investment Management’s Portfolio LIMNW Stock Details LIMNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50 Hold
1,250
– – ﹤0.01% 165
2025
Q4 		$44 Hold
1,250
– – ﹤0.01% 158
2025
Q3 		$185 Hold
1,250
– – ﹤0.01% 121
2025
Q2 		$300 Buy
+1,250
New +$246 ﹤0.01% 98

Other funds holding LIMNW

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.4% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

HGC Investment Management's LIMNW Position: Q1 2026 in Review

HGC Investment Management held its Liminatus Pharma Warrants (LIMNW) position steady in Q1 2026 at 1,250 shares worth $50. The position accounts for ﹤0.01% of the portfolio, ranked #165.

HGC Investment Management first reported a position in LIMNW in Q2 2025 and has held it in 4 quarters since. The position peaked at $300 in Q2 2025. 21 funds tracked by Wall St. Rank hold LIMNW as of Q1 2026.

  • HGC Investment Management held 1,250 shares of Liminatus Pharma Warrants worth $50 as of Q1 2026.
  • HGC Investment Management left its Liminatus Pharma Warrants share count unchanged in Q1 2026.
  • Liminatus Pharma Warrants made up ﹤0.01% of HGC Investment Management's portfolio in Q1 2026, its #165 holding.
  • HGC Investment Management first reported a position in Liminatus Pharma Warrants in Q2 2025 and has held it in 4 quarters since.
  • HGC Investment Management's Liminatus Pharma Warrants position peaked at $300 in Q2 2025.
  • 21 funds tracked by Wall St. Rank held Liminatus Pharma Warrants as of Q1 2026.

Based on HGC Investment Management's 13F filing for Q1 2026, filed 15 May 2026.